Beata Dizoglio, MD
Obstetrics & Gynecology · Providence, RINPI 1558581165
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AbbVie at 54.1% of the total. Reporting peaked in 2023 at $2,534 and has fallen 79.7% since, to $514 in 2025. Among obstetrics & gynecology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $37.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Exeltis, USA Inc.$433
- Sumitomo Pharma America, Inc.$312
- Astellas Pharma US Inc$262
- Myovant Sciences Inc.$261
- Pfizer$208
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$2,50043%
- Food & beverage$3,23555%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $3,156 |
| Exeltis, USA Inc. | 15 | $433 |
| Sumitomo Pharma America, Inc. | 15 | $312 |
| Astellas Pharma US Inc | 7 | $262 |
| Myovant Sciences Inc. | 14 | $261 |
| Pfizer | 12 | $208 |
| Merck | 10 | $192 |
| Coopersurgical, Inc. | 5 | $117 |
| Mylan Pharmaceuticals Inc. | 6 | $115 |
| Bayer | 5 | $97 |
| Exact Sciences | 4 | $90 |
| Sage Therapeutics, LLC | 4 | $90 |
| Therapeuticsmd, Inc. | 5 | $84 |
| Scynexis, Inc. | 3 | $76 |
| Agile Therapeutics, Inc. | 3 | $66 |
| Mayne Pharma Commercial LLC | 2 | $45 |
| Evofem Biosciences, Inc. | 2 | $39 |
| Lupin Inc. | 2 | $35 |
| Medicem Inc. | 2 | $27 |
| Covidien LP | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Shield Therapeutics Inc | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Roche Diagnostics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,835 in reported general payments places this provider in the 90th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremproEstrogen,con/M-Progest Acet | 17 | $5,664 |
| PremarinEstrogens, Conjugated | 12 | $3,349 |
| Estradiol (Once Weekly)Estradiol | 22 | $1,449 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $500 |
| Clobetasol Propionate | 15 | $230 |
| Triamcinolone Acetonide | 27 | $225 |
| Junel FeNorethindrone-E.Estradiol-Iron | 14 | $217 |
| Estradiol | 12 | $207 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $196 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $142 |
| Misoprostol | 18 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPrempro, Premarin | $208 | $9,01329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Other obstetrics & gynecology in Providence
- Warren HuberProvidence$50K
- Lisa BoyleProvidence$30K
- Renee EgerProvidence$24K
- Gary WhartonProvidence$22K
- Christine FoleyProvidence$21K
- Cara MathewsProvidence$21K
- Michael BeitleProvidence$9K
- Ogechukwu EzikeProvidence$7K
- Michele GangeProvidence$5K
- Caitlin Saint AubinProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.